Drug intelligence / Profile preview

DF-X1

Development stage: Preclinical
Lead developer: Drug Farm

Overview

DF-X1 is an early-stage drug candidate being developed by Drug Farm (Shanghai Drug Farm Biological Technology Co., Ltd.) for the treatment of colitis. As of early 2024, the program is in the target discovery phase, representing the earliest stage of the company's pipeline for digestive system disorders. Specific details regarding its molecular target, mechanism of action, and modality have not yet been publicly disclosed. The program is distinct from DF-004, another colitis candidate in the company's pipeline that has progressed to the candidate selection stage.

Beyond the preview

Go deeper on DF-X1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DF-X1.

Explore the full profile